An Early-Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) In Pediatric and Young Adult Patients With Previously Treated Solid Tumors

Trial Profile

An Early-Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) In Pediatric and Young Adult Patients With Previously Treated Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Ewing's sarcoma; Hodgkin's disease; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdoid tumour; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Acronyms iMATRIX
  • Sponsors Roche
  • Most Recent Events

    • 06 Jun 2017 According to results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, new cohorts are planned in rhabdoid tumor (RT) and atypical teratoid rhabdoid tumor (RT) .
    • 06 Jun 2017 Results (n=74, as of 19 Jul 2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 01 Apr 2017 The trial has been Discontinued Austria.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top